Adjunctive Cariprazine as a Novel Effective Strategy for Treating Major Depressive Disorder： A Systematic Review and Meta-Analysis

Abstract

e v i e w q u e s t i o n / O b j e c t i v e ( 1 ) Participants: individuals aged 18 to 65 who h a v e b e e n d i a g n o s e d w i t h m a j o r depressive disorder; (2) Intervention: patients who were administered cariprazine in addition to their antidepressant medication; (3) Comparison: patients who received a combination of placebo and antidepressant medication; (4) Outcomes: the effectiveness outcomes included the evaluation of changes in various assessment scales, such as the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression Scale (17 items), the Clinical Global Impressions severity, the Clinical Global Impressions improvement, the MADRS response, the MADRS remission, and the CGI-I response. Safety results encompassed the occurrence of adverse events and serious major adverse events;(5) study type: study type was randomized clinical trials. Condition being studiedThe objective of this study is to explore the efficacy and safety of cariprazine as an adjunctive treatment for major depressive disorder. Current approaches for patients with insufficient response to first-line antidepressants include combination therapy using multiple antidepressants concurrently, as well as t h e u s e o f m o o d s t a b i l i z e r s o r a t y p i c a l antipsychotics to enhance the effectiveness of ADTs. Cariprazine has shown promise as an adjunctive therapy with antidepressants for major depressive disorder. This study involved a comprehensive literature review of cariprazine, utilizing databases such as Embase, PubMed, and the Cochrane Library. Through the comparison of these trials, the aim of this study is to provide valuable insights into the effectiveness of adjunctive cariprazine in managing major depressive disorder.